Advancing Next Generation Cancer Treatment
Ariceum Therapeutics, a pharmaceutical company based in Berlin’s famous health district Buch, focuses on the diagnosis and precision treatment of certain aggressive, hard-to-treat cancers. The name Ariceum is an anagram of ‘Marie Curie’. Ariceum’s lead product ‘Satoreotide’ is being developed for the combined diagnosis and targeted treatment of the tumors of some aggressive cancers, such as small cell lung cancer (SCLC), which currently have few treatment options and poor prognosis. Ariceum have announced that they have raised an additional €23M, making their series A round total €48M. The money will be used to extend the clinical development and therapeutic administrations of Satoreotide, making the drug ready for the market. “The additional investment is a strong endorsement of our targeted radiotherapy product and reflects the opportunity that radiopharmaceutical drugs offer in visualizing and treating cancer,” says CEO Manfred Rüdiger, PhD.